User: Guest  Login
Document type:
journal article 
Author(s):
Schmutzler, RK; Meindl, A 
Title:
The first targeted therapy in ovarian cancer permitted for BRCA1/2 mutation carriers 
Abstract:
Olaparib (Lynparza (TM)) is an oral, small-molecule, poly (ADP-ribose) polymerase (PARP) inhibitor being developed by AstraZeneca for the treatment of solid tumours. The primary indication for which olaparib is being developed is BRCA1/2 mutation-positive ovarian cancer. A capsule formulation of the drug has received approval for use in this setting in the EU by the European Medicines Agency (EMA). The application of olaparib has been indicated for germline and somatic mutations in BRCA1 and/or...    »
 
Journal title abbreviation:
Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V. 
Year:
2015 
Journal volume:
27 
Journal issue:
Pages contribution:
228-230 
Language:
de 
Print-ISSN:
0936-5931 
TUM Institution:
Frauenklinik und Poliklinik